Apr. 7 at 5:26 PM
$IH In the China's smallcap space, iHuman is a unique case.
Advantages:
1. It is moderate in dilution, the No 1 problem of such stocks.
2. It trades above
$1: the No 2 danger for such stocks is a reverse split.
3. It's an ADS, so no "A" and "B" shares with different right in votes, to dilute endlessly.
4. It is debt-free.
5. It trades at a huge negative Enterprise Value.
6. It is profitable with low P/E.
7. It is very near its multi-year lows.
8. Seasonality: In 2023, 2024 and 2025 IH bottomed around this time of the year.
9. The daily volume has dropped a lot, it drained, primed for a reaction.
10. They have announced some significant deals in late 2025.
11. Last year they declared a
$0.10 dividend, in April 17.
Disadvantages:
1. It doesn't belong to a fancy industry.
2. They 2025 revenues was decreased a bit, also the EPS.
3. Its market cap is not very low, like those microcaps that penny flippers love to trade.
4. It won't make you rich, usually it rallies about 100%, not more.
